This trial is for patients who have cancer cells still in the blood or bone marrow after approximately one year of lenalidomide maintenance therapy following a stem cell transplant
This trial is testing if the addition of immunotherapy to the usual treatment will lead to better results for patients with esophagus or gastroesophagus cancer